ESQUEMAS OPERACIONES MENTALESSE
ESQUEMA DEL PENSAMIENTO FORMAL DESDE UN RAZONAMIENTO HIPOTÉTICO DEDUCTIVO
3.4. PRINCIPALES CRÍTICAS A LA TEORÍA DE PIAGET
(a) Always less than 7.0mmol/l (b) Between 7.0-10.0mmol/l (c) Always greater than 10.0mmol/l
SECTION C
1. Are you a known chronic kidney disease patient?
(a) Yes (b) No
2. Have you been told that you had acute kidney failure in the past?
(a) Yes (b) No
3. Do you have any family member who is a known diabetic?
(a) Yes (b) No
3b. If yes, who (a) father (b) mother (c) brother (d) sister (e) aunt (f) uncle (g) cousin
4. Do you have any family member who has CKD from diabetes?
(a) Yes (b) No
4b. If yes, who (a) father (b) mother (c) brother (d) sister (e) Aunt (f) uncle (g) cousin
5. Are you a known hypertensive?
(a) Yes (b) No
6. If yes, when was it diagnosed?
(a) Before diagnosis of DM (b) After diagnosis of DM.
7. Are you on anti -hypertensive medication? (a) Yes (b) No If yes, which one (a) Diuretics (b) ACEI (c) CCB (d) ARB (e) Others
8. Do you smoke?
(a) Yes (b) No
9. If Yes, how many cigarettes a day (a) less than 5 cigarettes daily (b) 6- 20 cigarettes daily (c) greater than 20 cigarettes daily.
10. Duration of smoking.
(a) Less than 5 years (b) Between 6 and 10 years (c) Above 11 years 11. Do you take alcohol?
(a) Yes (b) No
77
11b. If yes, what quantity of alcohol a day? (a) 1- 4 bottles of beer in a day (b) 5-10 bottles of beer in a day (c) more than 10 bottles per day (d) less than 5 glasses of wine per day (e) more than 5 glasses of wine per day (f) less than 5 tot of local gin per day (g) more than 5 tot of local gin in a day.
12. Do you consider yourself to be obese?
(a) Yes (b) No.
78 SECTION D
PHYSICAL EXAMINATION a) Height (m)
b) Weight (kg)
c) Waist circumference (cm) d) Body mass index (BMI) kg/m2
e) Pallor Yes No
f) Pyrexia Yes No
g) Pedal/sacral edema Yes No h) Pulse rate at presentation
i) Blood pressure at presentation
j) Jugular venous pulsation Normal, Elevated
k) Apex beat Normal, Displaced laterally And downward l) Extra heart sound S3, S4, Gallop rhythm
m) Murmur Present, Absent
n) Crackles Nil, Bilateral basal fine, o) Bronchial breath Nil, Present
p) Hepatomegaly Nil, Present q) Funduscopy findings………..
79 SECTION E
LABORATORY INVESTIGATIONS 1. Hemoglobin level ( g/l )
2. White blood cell count ( total and differential) 3. Serum urea - mmol/l
4. Serum creatinine - mol/l 5. Reticulocyte count 6. Urinalysis
7. Fasting blood sugar (plasma glucose) -mmol/l 8. Chest x-ray
9. Peripheral blood film 10. Fasting lipid profile
11. Abdominopelvic ultrasound.
80
REFERENCES
1. BMC Public Health: Prevalence of chronic kidney disease in population-based studies: Systemic review: QUI-Li Zhang and Dietrich Rothenbacher BHC. Public Health 2008; 8-117.
2. World Health Organization: Global burden disease. 2006 March.
Available from http://www.int/whosis/menu.<fm path = evidence.
(Accessed August, 2011.)
3. Rychlik I, Miltenbeger-Miltenyi G, Ritz E. The drama of the continous increase in end stage renal failure with type 2 diabetes mellitus. Nephro dial transplant 1998; (Supl 8) 6-10.
4. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Disease causing chronic renal failure in Nigeria. A prospective study of 100 cases. Afri J Med and Med Sci 1989; 18(2) 131-7.
5. Alebiosu CO, Ayodele OO, Abbas A, Olutoyin AI. Chronic renal failure at the Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria. Afr.
Health Sci 2006; 6(3) 132-38.
6. Ulasi I, Ijoma CK. The enormity of chronic kidney disease in Nigeria. The situation in a teaching hospital in the South-East Nigeria.J.T Med. 2010 (2010) 501917-103.
7. Renal Data System. USRDS 2000 annual data report.Bethesda, Md.
National Institute of Diabetes and Digestive and Kidney Disease, 2001.
http://www.org/adr 2000.htm.
81
8. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The Kidney in maturity onset diabetes mellitus: a clinical study of 570 patients. Kid Int 1982; 21: 730-8.
9. Ritz E, Stenfenski A. Diabetic nephropathy in type 2 diabetes.Am J Kidney Dis 1996; 27:167-94.
10. Thangaraj Y, Gangav V, Puppala, Prabhakran A. Is Under-Diagnosis and Under-Recognition of chronic kidney disease playing a role in Higher prevalence of Atrial fibrillation? The Internet J of family practice. 2010;
9(1).
11. Middleton RJ et al. The unrecognized prevalence of chronic kidney disease in diabetes. Oxford J Med Nephrol. Dial Trans. 2005; 21(1): 88-92.
12. Bello AK, Nwankwo E, El Nahas AM. Chronic kidney disease. A global challenge. Kid Int 68(Suppl 98) 2005; 511-17.
13. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Chronic Kidney Disease Evaluation, Classification and Stratification.
AMJ Kidney Dis 2002; 39(Suppl 1): S1-266.
14. American Journal of Kidney Disease Position Statement. Definition and Classification of Chronic Kidney Disease: The debate should be about patient prognosis- a positon statement from KDOQI and KDIGO; 2009 20(10).
82
15. National Health and Nutrition Examination Survey (NHANES 111).Website:www.pop.psu.edu/dataarchive/daman/nhanes4.htm.
16. Chronic Kidney Disease in the Developing world. N Engl J Med 2006 ; 354 (10):9979.http//content.nejm.org/cgi/content/full/354/10/99.
17. Barsoum RS. Chronic kidney disease in the developing world. Artif organs 2002; 26: 736-7.
18. Adetuyibi A, Akisanya JB, Onadeko BO. Analysis of the cause of death in the medical wards of the University college Hospital, Ibadan, over a 14 years period (1960-1973). Transaction of the Royal Society of J Med. and Hyg. 1976; 70(5-6): 466-73.
19. Kuteyi A, Akinbola A, Ezeoma IT. Renal disease: The need for community- based screening in rural Nigeria. Afr. J Med pract 1999;6(5):
198-201.
20. Nwankwo EA, Nwankwo B, Mubi B. Prevalence of impaired kidney function in hospitalized hypertensive patients in Maiduguri, Nigeria. The Int. J. Int. Med. 2006; 6(1).
21. Soman SS, Soman AS. Diabetes Nephropathy, e medicine endocrinology.
Nov 19, 2009. e medicine medscape.com/art/238946.
22. Mogensen CE, Chachati A, Chritensen CK. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia invest 1985;9: 85-95.
83
23. Orchard TJ, Dorman JS, Maser RE. Prevalence of complications in IDDM by sex and duration. Pittsburg Epidemiology of Diabetes complications study II. Diabetes 1990; 39:1116-24.
24. Newman DJ, Mattock MB, Dawnay AB. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9(30) 13-163.
25. Parving HH, Hommel E, Mathiesen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and nephropathy in patients with insulin dependent diabetes. Br Med J 1988; 296:156-60.
26. Ismail N, Becker B, Strzekzyk P, Ritz E. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 1999; 55:1-26.
27. Krolewski AS, Warram JH, Christlieb AR. The changing natural history of nephropathy in type 1 disease. Am J Med 1985; 78:785-94.
28. Matshushima M, Tajima N, Laporte RE. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny county Pennysylvania, USA. Diabetes Epidemiology Research International (DERI) U.S-Japan Mortality Study Group. Diabetologia 1995; 38:236-43.
29. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35year follow-up study. Kidney Int 1996; 50:2041-46.
30. Cowie CC, Port FK, Wolfe RA. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321:1074-79.
84
31. Nelson RG. Knowler WC, Pettit PJ. Diabetic kidney disease in Pima Indians Praseter Care 1995; 16:335-41.
32. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127-33.
33. Adler AI, Steben RJ, Mankey SE, Bilous RW. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 65:225-32.
34. Unuigbe EI, Omeife H, Edema T, Ukoli FA. Microlbuminuria and associated factors in newly diagnosed diabetics. Niger Postgrad Med J.
2001;8(4):187-92.
35. Erasmus RT, Oyeyinka G, Arije A. Microalbuminuria in Non-insulin dependent(type2) Nigerian diabetes:relation to glycemic control,blood pressure and retinopathy. Postgrad Med J.1992; 68:638-42.
36. Agaba EL, Agaba PA, Puepet FH. Prevalence of microalbuminuria in newly diagnosed diabetic patients in Jos, Nigeria. Afr J Med. 2003; 33(1):
19-22.
37. Alebiosu CO. Clinical diabetic nephropathy in a tropical African population .West Afr J Med. 2003; 22(2): 152-55.
38. Ejuogharan OJO, Chukwu EO, Fidelis OE. Incidence of Diabetic nephropathy in Southern Nigeria. J Med Sci 9; 264-69.
39. Maduka IC, Neboh EE, Kwusiri UC. The prevalence of Diabetic nephropathy in diabetic patients. European J of Scientific Research.
ISSN 2009; 1450-2166, 26(2):255-59.
85
40. Afifi A, Elsetouby M, Elsharkawy M. Diabetic nephropathy as a cause of end-stage renal disease in Egypt: a six year study. East Mediterr Health J. 2004; 10(4-5):620-26.
41. Fioretto P, Staffes MV, Brown DM, Mauer SM. An overview of renal pathology in insulin dependent diabetes mellitus in relationship to altered glomerular hemodynamics. AMJ Kidney Dis 1992; 20:549-58.
42. Ruggenenti P, Bambara Petna A. The nephropathy of non-insulin dependent diabetes. Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998; 9:2336-43.
43. Harris RD, Steffes MW, Bilous RW. Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 1999; 40:107-14.
44. Mongessen CE. Renal function changes in diabetics. Diabetes 1976;
15(2):872-79.
45. Hilgers KF, Veelkens R. Type 2 diabetic nephropathy: Never too early to treat? J Am Soc Nephrol 2005; 16:574-75.
46. Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991;
40:792-807.
47. Serri O, Beauregard H, Bruzeau P. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991; 265:888-92.
48. Hirschberg R, Brunori G, Kopple JD, Guler HP. Effects of insulin-like growth factor 1 on renal function in normal men. Kidney Int 1993;
43:387-89.
86
49. Anderson S, Vora JP. Current concept of renal hemodynamics in diabetes. J Diabetes Complications 1995; 9:304-07.
50. Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglcemia and angiotension – converting enzymes inhibition in diabetes. Kidney Int 2005; 68:1722-28.
51. Passariello N, Sepe J, Marrazzo G. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and GFR in IDDM subjects with nephropathy. Diabetes care 1993; 16:789-96.
52. Valton V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003; 14:530-37.
53. Hannedouche TP, Delgado AG, Gnionsache DA. Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int.
1990; 37:1126-33.
54. Matika Z, Radott S, Rayfield EJ. Advance glycosylation end products in patients with diabetes nephropathy. N Engl J Med 1991; 325:836-92.
55. Coper ME. Pathogenesis, prevention treatment of diabetic nephropathy.
Lancet 1998; 352:213-19.
56. Maxhimer JB, Somenek M, Rao G. Heperanase – 1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54:21-72.
87
57. Wilson DM, Luetscher JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990;
323:1101-06.
58. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503-56.
59. Ichihara A, Suzuki F, Nakagawa T. Protein receptor blockade inhibits development of glomerusclerosis in diabetic angiotension II type 1 a receptor deficient mice. J Am Soc Nephrol 2006;17:1950-61.
60. Wolf G, Ziyadeh FN. Molecule mechanisms of diabetic renal hypertrophy.
Kidney Int 1999; 56:393-405.
61. Hohenstein B, Hauskenecht B, Bochmer K. VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
Kidney Int 200; 69:1654-61.
62. Sharma K, Ziyadeh FN. Hyperglycemics and diabetic kidney disease: The case for transforming growth factor B as a key mediator. Diabetes 1995;
44:1139-46.
63. Wang S, Decaestecker M, Kopp L. Renal bone morphogenetic protein – 7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;
17(9):504-12.
64. Sharma K, Eltayeb BO, McGowan TA. Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients: Am J Kidney Dis 1999; 34:818-23.
65. Janssen B, Hohenadel P, Brinkkoetter P. Cernosine as a protective factor in diabetic nephropathy: association with a leucine repeat of carnosinase gene CNDPI. Diabetes 2005; 54:2520-30.
88
66. Benigni A, Gagliardini E, Tomasoni S. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy.
Kidney Int 2004; 65:213-19.
67. Trevisan R, Viberti G. Genetics factors in the development of diabetic nephropathy. J Lab Clin Med 1995; 126:342-49.
68. Pettit DJ, Saad MF, Bennett PH. Familial predisposition to renal disease as two generations of Pima Indians with type 2 (non-insulin dependent) diabetes mellitus.Diabetologia 1990; 33:438-43.
69. Jeffers BW, Eastagio RO, Raynolds MV, Schrier EW. Angiotensin – converting enzyme gene polymorphism in non-insulin dependents diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1998; 52:473-77.
70. Petterson-Fernholm K, Frojdo S, Fagerudd J. The AT2 gene may have a gender specific effect on kidney function and pulse pressure in type 1 diabetic patients. Kidney Int 2006; 69:1880-84.
71. Tapp RJ, Shaw JE, Zimmet PZ. Albuminuria is evident in the early stages of diabetes onset: result from the Australian Diabetes, obesity, and lifestyle (Aus Diab). AMJ Kidney Dis 2004; 44:742-57.
72. Svensson M, Nystrom L, Schon S, Dahiquist G. Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease and mortality in young and middle-aged Pima in Indians. JAMA 2006; 296:421-26.
73. Mogensen CE, Hansen KW, Pedersen MM. Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes care 1991; 14 (suppl 7) 4:13-26.
89
74. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;
11:309-17.
75. Randeree HA, Omar HA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes care 1992; 15:1258-63.
76. Nosadini R, Sambataro M, Thomuseth K. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin dependent diabetes. Kidney Int 1993; 44:139-46.
77. Cruick Shank K, Riste L, Anderson SG. Aortic-pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106:2085-90.
78. Rudgerg S, Persson B, Darhlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy. An 8 year prospective study.
Kidney Int 1992; 41:822-28.
79. Vora JP, Polben J, Dean JD. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 418-29.
80. Odutola TA, Mabedeje AF, Mabayoje MO. Effects of DM on glomerular filtration rate in an urban hospital diabetic population. Afr J Med sci 1997; 26(1-2) 19-21.
90
81. The diabetes control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus. N Engl Med 1993; 329:977-86.
82. Broncatii FL, Whittle JC, Whelton PK. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA 1992; 268:3079-84.
83. Kohles KA, McCuellan WM, Ziener DC. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. AM J Kidney Dis 2000; 36:903-13.
84. Schmidk K, Pesce C, Liv Q. Large glomerular size in Pima Indians: Lack of change in diabetic nephropathy J Am Soc Nephrol 1992; 3:229-35.
85. deBoer IH, Sibley SD, Kestnebaum B. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18:235-43.
86. Morales E, Valero MP, Leon M. Beneficial effects of weight loss in over weight patients. AMJ Kidney Dis 2003;41(2):319-27.
87. Facchini FS, Hollenbeck CB, Jeppesen J. Insulin resistance and cigarette smoking. Lancet 1992; 339:1128-30.
88. Zoppini G, Torgher G, Cacciatori V. Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1levels. Diabetes care1999; 22(11)1871-74.
91
89. Ahmed SB, Hovind P, Parving HH. Oral contraceptives, angiotension-dependent renal vasoconstriction and risk of diabetic nephropathy.
Diabetes care 2005; 28:1988-94.
90. American Diabetes Association: Nephrology in diabetes (position statement). Diabetes care 27( Suppl 1) 2004 ;579-83.
91. European Diabetes Policy Group. A desktop guide to type 2diabetes.
Diabet Med 16 1999; 416-730.
92. Eknoyan G.et al. Proteinuria and other markers of chronic kidney disease. A position statement of the NFK and the NIDDK diseases. AM J kidney Dis 2003; 42:617-22.
93. Zelmanovitz T. et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes care 1997; 20: 516-19.
94. Sacks DC.et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of DM.Clin chem. 2002;48 436-72.
95. Levey AS, Kausz AT, Eknoyan G. National kidney Foundation Practice Guidelines for CKD. Evaluation,Classification, and Stratification. Ann Intern Med 2003; 139: 137-47.
96. Mauer M, Fioretto P. In Disease of the Kidney and urinary tract.7th ed.
Schrier RW, ed. Lippcott William$ Wilkins2000; 2083-2116.
97. Marshal SM, Shearing PA, Alberti KGMM. Micral – test strips Evaluated for screening for Albuminuria. CLIN.CHEM 1992; 38(4):588-591.
92
98. Report of WHO Scientific Group; Cardiovascular disease risk factors; new areas for research. WHO Technical Report Series. No 841.WHO Geneva 1994.
99. WHO: The problem of overweight and obesity 2000: preventing and managing the global epidemic. In Report series 894.wt.Geneva; WHO:
2000: 537.
100. Guesseous I, McClellan W, Vupputri S, Wasse H. Low documentation of chronic kidney disease among high – risk patients in managed care population; A retrospective cohort study. BMC Nephrol,2009,10-25.
101. Plantinga LC.etal. Patient awareness of chronic kidney disease. Trends and predictors .Arch intern med.2008;168:2268-75.
102. Sumaili EK. et al. High prevalence of undiagnosed chronic kidney disease among at risk population in Kinshasa, the democratic republic of Congo.
BMC Nephrol, 2004; 10:18.
103. Trannews. Incidence of ESRD in diabetics declining, but undiagnosed patients found to have increased in chronic kidney disease. Transplant e news Mar. 2010.
104. New JP et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetics compared with those without diabetes in general practice Diabet Med. 2007; 24: 364-69.
93
105. Coresh J, Astor BC, Greene T, Eknoyan G. Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. AM J kidney Dis 2008; 41:1-12.
106. Awobusuyi J.O, Kukoyi OO. Ibraham MA, Atiba M. Indices of kidney damage and cardiovascular disease risk factors in a semi urban community of Iloye, South-West Nigeria Int. J Nephrol. 2011 (2011).
107. Duru Ok, Vargos RB, Kernah D, Nissenson AR, Worris KC. High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine. J Gen Intern med. 2009; 24: 86-92.
108. Hanna BG. et al. Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention. Nephrol; 11:549-54.
109. dezeeuw D. et al. Proteinuria a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL kidney Int. 2004;
65:2309-20.
110. American Diabetes Association. Standards of medical care in diabetes.
Diabetes care 2011; 34(Suppl 1) 511-5.
111. Sanusi AA, Arogundade FA, Akintomide AO, Akinsola A. Utility of predicted creatinine clearance using MDRD formula compared with other predictive formulas in Nigerian patients. Saudi J Kidney Dis Transpl.
2009; 20(1):86-90.
94
112. Agaba EI, Wigwe CM, Agaba PA, Tzamaloukas AH. Performance of the Cockcroft-Gault and MDRD equations in adult Nigerians with chronic kidney disease. Int Urol Nephrol. 2009; 41(3):635-42.
113. Gupta.et al. The prevalence of microalbuminuria in diabetes: a study from North India. Diabetes Res Clin Pract 1991; 12:125-28.
114. John L. et al. Prevalence of diabetic nephropathy in non-insulin dependent diabetes. Indian J Med. Res 1991; 94:24-29.
115. Vijay et al. Prevalence of proteinuria in non-insulin dependent diabetes.
J Assoc Physicians 1994; 42: 792-94.
116. Marshal SM, Albert KGMM. Comparison of the prevalence and associates features of abnormal albumin excretion in insulin-dependent and non-insulin dependent diabetes. J Med. 1989; 70:61-71.
117. Nelson RG.et al. Albuminuria in type 2 (Non-insulin dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia.
1989; 32:870-76.
118. Collins.et al. Prevalence and risk factors for micro and macro albuminuria in diabetic subjects and entire population of Naurau. 1989;
38:1602-10.
119. Hamman RF. et al. Microvascular complication of NIDDM in Hispanics and non Hispanics white. 1991; Diabetes care 14: 655-63.
120. Vijay et al. Familial aggregation of diabetic kidney disease in type 2 diabetes in South India. Diabetes Res Clin Pract 1993; 43:167-71.
95
121. Bhaskaw T, Khiti A, Ritesh V, Moshin L, Agnihotri. Prevalence of microalbuminuria in newly diagnosed type 2 diabetes mellitus NJIRM.
2011: 2(4).
122. Parving H.H. et al. Prevalence of diabetes mellitus in North-Western Tanzania. Diabetologia. 1984; 26; 333-36.
123. Klein R. et al. The 10-year incidence of renal insufficiency in people with type 1-diabetes. Diabetes care. 1990; 22:743-57.
124. Abdul – Ramman AW, Olufunsho F. Hyperlipidaemia among Saudi diabetic patients – pattern and clinical characteristics. Ann Saudi Med 1995; 15(3) 240-43.
125. Agaba IE, Anteyi EA, Puepet FN, Omudu PA, Idoko JA. The clinical pattern of diabetic nephropathy in type II diabetes mellitus in North Central Nigeria. J of Med in the tropics 2002; 4(2)1.
126. Thomas MC. et al. Serum lipids and the progression of nephropathy in type I diabetes. Diabetic care 2006; 29:317-22.
127. Conrad KA.et al. Predictors of microalbuminura in individuals with IDDM. Pittsburgh epidemiology diabetes complications study. Diabetes care 1993; 10:1613-76.
128. Metcalf P. et al. Albuminuria in people at least 40years old: effects of obesity, hypertension, and hyperlipidaemia. Clin Chem 1992; 38:1802-08.
96
129. Tozawo M. et al. Triglyceride, but not total cholesterol or low density lipoprotein cholesterol levels, predict development of proteinuria.
Influence of smoking and obesity on the development of proteinuria.
Kidney Int 2000; 62:1703-49.
130. Schaeffner.et al. Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 2003; 14: 2083-91.
131. Mutner.et al. Plasma lipids and risk of developing renal dysfunction. The atherosclerosis risk in communities study. Kidn ey Int. 2000; 58:298-301.
132. Ismail N. Renal disease and hypertension in Non insulin- dependent DM.
Kidney Int.1999:55; 1-28.
133. Idogun ES, Unuigbe EI, Famodu A.A, Akintola OT. Body mass index in type 2 diabetes mellitus complication: hypertensive diabetics and diabetic nephropathy. The Nigerian Postgraduate Med. J. 2006; 1391) 17-20.
134. De Jong PE, Vehave JC, Pinto – Sietsma SJ, Hillege HL. PREVEND Study Group. Obesity and target organs damage: The Kidney. Int J Obes Relat Metab Discord 2002: 26(Suppl 4); S21-S24.
135. Iseki K. et al. Body mass index and the risk of development of end-stage renal disease in a screened cohorts. Kid Int.2004; 65:1870-76.
136. Fox.et al. Predictors of new – onset kidney disease in a community – based population. JAMA 2004; 291: 844-50.
97
137. Mulder WJ, Hillen HFP. Renal function and renal disease in the elderly.
Eur J Int Med.2001; 12: 86-97.
138. Rowe JW.et al. The effect of aging on creatinine clearance in men; a cross sectional and longitudinal study. J Ger.1996; 31:155-63.
139. Gall MA.et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with NIDDM: prospective observational study.
BMJ 1999; 314:783-88.
140. Klein.et al. The lower incidence of renal insufficiency in people with type 1 diabetes. Diabetes care 1999; 22:743-51.
141. Afolabi MO, Abioye-kuteyi EA, Arogundade FA, Bello IS. Prevalence of Chronic Kidney Disease in a Nigerian family practice. SA fam pract 2009;51:32-7.
142. Norimich T. etal. Risk factors for chronic kidney disease in Japan- a community-based study. BMC Nephrol 2009. (vol 10).
143. Knight EL. et al. Moderate alcohol intake and renal function decline in women: a prospective study. Nephrol Dial Transplant 2003; 18:1549-54.
144. Perneger.et al. Risk of end-stage renal disease associated with alcohol consumption. AM J Epidemiol 1999:150;1275-81.
145. Ulasi I, Ijoma C, Arodiwe E, Okoye J, Ifebunandu N. Lifestyle Risk Factors. Do they contribute to CKD in developing countries? The Int. J of nephrol, 2010 ; 6(1).